ABSTRACT

Chronic thromboembolic pulmonary hypertension (CTEPH) is a serious and debilitating disease caused by occlusion of the pulmonary arterial bed by hematic emboli and by the resulting fibrous material. Such occlusion increases vascular resistance and, consequently, the pressure in the region of the pulmonary artery, which is the definition of pulmonary hypertension. The increased load imposed on the right ventricle leads to its progressive dysfunction and, finally, to death. However, CTEPH has a highly significant feature that distinguishes it from other forms of pulmonary hypertension: the fact that it can be cured through treatment with pulmonary thromboendarterectomy. Therefore, the primary objective of the management of CTEPH should be the assessment of patient fitness for surgery at a referral center, given that not all patients are good candidates. For the patients who are not good candidates for pulmonary thromboendarterectomy, the viable therapeutic alternatives include pulmonary artery angioplasty and pharmacological treatment. In these recommendations, the pathophysiological bases for the onset of CTEPH, such as acute pulmonary embolism and the clinical condition of the patient, will be discussed, as will the diagnostic algorithm to be followed and the therapeutic alternatives currently available.

Keywords: Hypertension, pulmonary/diagnosis; Hypertension, pulmonary/surgery; Hypertension, pulmonary/therapy; Hypertension, pulmonary/drug therapy; Pulmonary artery/pathology; Pulmonary embolism/complications.

DEFINITION

Chronic thromboembolic pulmonary hypertension (CTEPH) is a form of pulmonary hypertension (PH) that results from occlusion of the pulmonary circulation by residual organized thromboembolic material, with consequent pulmonary microvasculature remodeling, which is induced or enhanced by a combination of imperfect angiogenesis, reduced endogenous fibrinolysis, and endothelial dysfunction. In this process, there is a gradual replacement of the normal intimal endothelial layer, causing a reduction in the pulmonary vascular bed and a consequent increase in its resistance and, therefore, in the afterload of the right ventricle. The increased load imposed on the right ventricle leads to progressive right ventricular failure, which is the major factor responsible for the mortality associated with CTEPH. (1)

The definition of CTEPH is based on objective criteria (Chart 1). (2) Conceptually, the diagnostic criteria aim to exclude a potential component related to acute embolic material (hence the requirement of at least three months of full anticoagulation), to confirm occlusion with imaging methods (rather than only on the basis of clinical suspicion), and, finally, to confirm the presence of PH. It is important to understand this concept in the broader context of other causes of PH.

Multiple etiological processes may be responsible for the elevation of pressure in the pulmonary vascular system as opposed to the normal condition of low pressure and low vascular resistance. By definition, PH occurs when mean pulmonary artery...
In up to approximately 80% of the cases of CTEPH, the disease is preceded by an identified episode of acute pulmonary thromboembolism (PTE). During the acute event, there are several changes resulting from the presence of emboli, changes that are outside the scope of these recommendations. However, it is worth noting that an acute PTE episode can have three possible clinical outcomes: 1) right ventricular failure due to an acute increase in the afterload of the right ventricle, which can lead to death; 2) complete reperfusion of the pulmonary circulation in the medium term, which can be spontaneous (resulting from the action of endogenous thrombolytics) or secondary to treatment; or 3) partial reperfusion of the pulmonary circulation, with residual occlusion of part of the pulmonary circulation. It is believed that one year after an acute PTE episode adequately treated with anticoagulants, approximately 30% of patients will continue to have filling defects in the pulmonary circulation when reevaluated with ventilation/perfusion lung scintigraphy, although not all of those will be symptomatic. Patients with perfusion defects after an episode of acute pulmonary embolism who continue to have dyspnea but do not have PH at rest are classified as having chronic pulmonary thromboembolic disease (CPTED). In this group, symptoms are due to PH on exertion or to changes in ventilation and gas exchange. In contrast, patients with residual perfusion defects, symptoms of even greater relevance, and PH are characterized as having CTEPH.

Unlike patients with CPTED, patients with CTEPH have marked hemodynamic dysfunction not only because of the hypoperfused vascular region (due to chronic pulmonary artery occlusion), but also because of clot-free lung regions, which are subjected to relatively increased flow, given that the blood flow diverted from the obstructed regions. In addition, it is speculated that bronchial circulation, whose flow is increased in such cases, may also lead to further increased flow in the vascular bed distal to the obstruction because of the presence of collateral circulation. This increased flow leads to endothelial dysfunction, with consequent vascular remodeling. As a result of this condition of regional hypoperfusion/ increased flow, susceptible patients develop PH and subsequent right ventricular failure. Therefore, endothelial dysfunction in CTEPH is found not only in the pulmonary artery region but also in the capillary and venous regions. This could explain why a considerable number of patients continue to have residual PH after pulmonary thromboendarterectomy (PTEA), a surgical procedure that is intended to cure CTEPH but that would not interfere with the disease affecting the pulmonary capillary and venous systems because it addresses only the fibrous material that is obstructing the pulmonary arteries.

**EPIDEMIOLOGY**

The prevalence of CTEPH after acute PTE is highly debatable, with rates ranging from 0.7% to 10% in the literature. A meta-analysis of 16 studies, involving 4,407 patients followed for more than two years, reported an overall incidence of 0.56% (95% CI: 0.1-1.0%). When only the patients who survived for at least six months after the embolic event were considered, the incidence was 3.2% (95% CI:

---

**Chart 1.** Diagnostic criteria for chronic thromboembolic pulmonary hypertension (all are required).

| Diagnostic criterion | | |
|---|---|---|
| Invasive confirmation of pulmonary hypertension: mean pulmonary artery pressure ≥ 20 mmHg* | Confirmation of pulmonary thromboembolism by pulmonary artery CT angiography, ventilation/perfusion lung scintigraphy, or pulmonary arteriography | At least three months of effective anticoagulation |

Adapted from Galiè et al. (2) Simonneau et al. (2)
The incidence of CTEPH in the global population is reported to be 5 new cases/million population per year, the mean age at diagnosis being 63 years and men and women being equally affected. Time to diagnosis is long, having been reported to be, on average, 14 months in a European cohort.

Contrary to what might be supposed, the risk factors for CTEPH are different from the classic predisposing factors for acute PTE, which have been associated with the classic triad described by Virchow: hypercoagulability; endothelial lesion; and venous stasis. Deficiencies of antithrombin, protein C, and protein S, as well as factor V Leiden mutation, have not been associated with the presence of CTEPH. However, high serum concentrations of factor VIII and the presence of lupus anticoagulant and antiphospholipid antibodies have been associated with the development of CTEPH, as has the presence of genetic variants that lead to fewer sites of binding of clots to plasmin, making the thrombi more resistant to lysis by endogenous thrombolytics.

The identification of familial clusters of CTEPH cases has also corroborated the role of genetic changes in the genesis of this disease. Various clinical comorbidities have also been associated with CTEPH: neoplasms; arteriovenous shunts; splenectomy; and chronic inflammatory diseases (such as inflammatory bowel disease, osteomyelitis, and rheumatoid arthritis). Very curiously, chronic infectious diseases, particularly bacterial ones, associated with infection with Staphylococcus aureus, appear to be related to the development of CTEPH. Fragments of S. aureus DNA have been isolated in the peripheral blood of patients with CTEPH, but not in patients with acute PTE. The greatest risk factor for the development of CTEPH in a European cohort was infection of cardiac pacemakers. In addition, in experimental models, the presence of S. aureus resulted in delayed recanalization of induced thrombi. Thyroid dysfunction, particularly that caused by thyroid hormone replacement therapy, has been identified as an independent risk factor for CTEPH. A recent study identified thyroid dysfunction in 10.5% of the patients with scheduled surgery, and, in 54.8% of those patients, there was no history of...
thyroid disease. Elevated levels of (endogenous or exogenous) thyroid hormones are associated with a higher risk of thrombosis secondary to an increase in factor VIII and von Willebrand factor, as well as with deficient fibrinolysis. The major risk factors for the development of CTEPH are described in Table 1.

**DIAGNOSIS**

The diagnosis of CTEPH is based on clinical status, imaging studies, and hemodynamic data. The main complaint is progressive dyspnea, most often preceded by an episode of acute PTE or deep vein thrombosis in the lower limbs. Physical examination can reveal a loud pulmonary component of the second heart sound and signs of right heart failure, with leg edema, ascites, and jugular stasis. Episodes of syncope may also be present. Hemoptysis is a more common symptom than in other forms of PH, being secondary to rupture of hypertrophied bronchial arteries.

Chest X-ray is of very limited importance in assessing CTEPH because it yields nonspecific findings, and echocardiography is commonly used as a screening test to investigate the presence of PH. One of the tests that can add sensitivity to the diagnosis of PH is cardiopulmonary exercise testing (CPET). CPET seeks to identify changes in oxygen consumption and carbon dioxide output during exercise, identifying the mechanism causing dyspnea; in early cases of PH, CPET can identify exertional limitation and increased physiological dead space.

Ventilation/perfusion lung scintigraphy (Figure 1) remains to be the test of choice for the investigation of cases of suspected CTEPH because of its high sensitivity (96–97%) and high specificity (80–95%), both of which are higher than those of conventional CT angiography (Figure 2). A meta-analysis evaluating CT angiography for the diagnosis of CTEPH reported an aggregate sensitivity of 76% (95% CI: 69–82%), despite a high specificity of 96% (95% CI: 93–98%).

Low probability scintigraphic findings exclude the diagnosis of CTEPH, which is not true for conventional CT angiography. More recent techniques, such as dual-energy CT angiography with iodine maps, have shown sensitivity and specificity similar to those of lung scintigraphy.

The most significant role of chest CT angiography is the diagnosis of acute PTE. In CTEPH, the greatest importance of chest CT angiography does not lie in excluding the diagnosis, but rather in making the differential diagnosis of CTEPH from other causes of vascular obstruction, as well as from lung parenchymal changes that might suggest the presence of heterogeneous perfusion (Figure 3). In addition, chest CT angiography has been a strategic tool for evaluating treatment options for CTEPH, together with lung scintigraphy and digital pulmonary angiography.

In conjunction with hemodynamic data, these tests can define the best therapeutic strategy: PTEA, considered the treatment of choice; balloon pulmonary angioplasty (BPA); or pharmacological treatment.

Chest CT angiography can also be useful in differentiating between acute PTE and CTEPH. There are radiological signs of chronicity of pulmonary vascular impairment that are identifiable on CT angiography and that make it possible to prevent inappropriate use of treatments for primary pulmonary reperfusion injury (thrombolysis or embolectomy) in cases initially diagnosed as acute events (Chart 3). Only patients with acute PTE and signs of hemodynamic instability should receive these treatments, not those with newly diagnosed CTEPH.

Magnetic resonance imaging (MRI) can be used for the differential diagnosis of CTEPH (from pulmonary artery sarcoma, for instance). In addition, cardiac MRI provides reliable information on cardiac chambers, allowing prognostic evaluation and the follow-up of interventions such as PTEA. Pulmonary artery magnetic resonance angiography is not usually used for the diagnosis of CTEPH for reasons of spatial resolution and logistics, although new techniques and equipment have improved its accuracy.

Similarly to MRI, positron-emission tomography-CT (PET-CT) can contribute to the differential diagnosis of CTEPH from diseases mimicking CTEPH. The role of PET-CT has been described in the identification of pulmonary artery sarcomas and Takayasu’s arteritis involving the pulmonary arteries. In both conditions, the uptake of glucose labeled with $^{18}$F-fluorodeoxyglucose measured with PET-CT is substantially increased in the vascular obstruction

### Table 1. Major risk factors for the development of chronic thromboembolic pulmonary hypertension.

| Risk factor                                      | OR (95% CI)          |
|--------------------------------------------------|----------------------|
| Infected pacemaker/arteriovenous shunts           | 76.40 (7.67-10.351)  |
| Splenectomy                                       | 17.87 (1.56-2.438)   |
| Recurrent venous thromboembolism events           | 14.49 (5.4-43.08)    |
| Thyroid hormone replacement therapy              | 6.10 (2.73-15.05)    |
| Previous venous thromboembolism event             | 4.52 (2.35-9.12)     |
| Antiphospholipid antibodies and lupus anticoagulant antibodies | 4.20 (1.56-12.21)    |
| History of malignancy                            | 3.76 (1.47-10.43)    |
| Blood type other than O                           | 2.09 (1.12-3.94)     |

Based on data from Bonderman et al. Independent risk factors when compared with those of patients with nonthromboembolic pulmonary hypertension; in that study, most patients had pulmonary arterial hypertension (group 1).
and distinguishes these conditions from CTEPH, given that the vascular occlusions in CTEPH generally do not show uptake of labeled glucose on PET-CT.

Invasive tests, such as right heart catheterization (RHC) and digital subtraction pulmonary arteriography (Figure 4), are key to preoperative assessment and to stratification of clinical and surgical risk in patients with CTEPH. RHC is mandatory to confirm the presence of PH, typically precapillary PH. Although some patients with CTEPH may show vasoreactivity, which may indicate a better prognosis, RHC is not performed at the treatment level, because it does not alter therapy. Given the complexity of these tests and their importance in defining the therapeutic approach, they should be performed at referral centers for CTEPH. The sequence of tests recommended for the investigation of CTEPH can be seen in Figure 5.
Regardless of the imaging method used, it is important to consider other diagnoses that can mimic CTEPH. As highlighted above, differentiation from acute PTE should always be sought. Large unilateral filling defects and/or intravascular lobulation suggest pulmonary artery sarcomas. The presence of multiple aneurysms and/or arterial wall thickening should raise the suspicion of pulmonary arterial vasculitis. Sometimes, abrupt termination of a major branch of the pulmonary artery, the causes of which can be a central thrombus, hypoplasia, or agenesis of the pulmonary artery, can be a diagnostic challenge. Large thrombi in situ, especially at bifurcation of pulmonary arteries and their branches, occurring more frequently in conditions of increased flow, such as in congenital heart disease with shunt, can also cause diagnostic difficulties in CTEPH.\(^{(38)}\)

**TREATMENT OF CTEPH**

**General approach**

Some approaches suggested for other forms of PH are also recommended for patients with CTEPH, although most of them have a low level of evidence. Chief among them are\(^{(2)}\): 1) female patients should avoid pregnancy and should be enrolled in specific education and follow-up programs, given the increased complexity associated with the use of hormonal contraceptive methods in this population; 2) physical

---

**Figure 3.** CT image on lung parenchymal window setting in a patient with chronic thromboembolic pulmonary hypertension. Note the mosaic perfusion pattern, with hypoperfused areas (black arrowheads) and hyperperfused areas (white arrowheads).

**Chart 3.** Pulmonary artery CT angiography findings suggestive of pre-existing chronic vascular disease.

| Direct vascular signs                                      |
|-----------------------------------------------------------|
| Eccentric filling defects that adhere to the vascular wall |
| Abrupt termination of a vessel                             |
| Complete vascular occlusion or concave or pouch-like defects |
| Intimal irregularity                                        |
| Linear intraluminal filling defects (such as bands or webs) |
| Stenosis or poststenotic dilatation                        |
| Vascular tortuosity                                        |

| Indirect vascular signs                                    |
|-----------------------------------------------------------|
| Significant right ventricular hypertrophy, right atrial dilatation |
| Pericardial effusion                                       |
| Pulmonary arterial dilatation (> 29 mm in men and > 27 mm in women) or pulmonary arterial wall calcification |
| Poststenotic dilatation of bronchial arteries resulting from obstructed vessels |

| Parenchymal changes                                        |
|-----------------------------------------------------------|
| Mosaic attenuation of the parenchyma as a consequence of geographic variation in perfusion |

Modified from Dias et al.\(^{(34)}\)
training programs can improve patient functional capacity; however, such programs should be started only after the use of specific treatments and under the supervision of teams with experience in caring for patients with PH; 3) immunization against influenza and pneumococcal infection should be performed during outpatient follow-up; 4) psychological and social support is desirable; 5) patients should be
advised of the risks of elective surgery and long air travel; 6) diuretics should be used in the presence of circulatory congestion associated with right ventricular failure; 7) the criteria for recommending home oxygen therapy are the same as those in patients with COPD, although there is no specific evidence for its use; and 8) it should be emphasized that there is no indication for the use of calcium channel blockers in CTEPH patients.

**Anticoagulation**

All patients with CTEPH should receive full anticoagulation indefinitely as from the time of diagnostic suspicion. Confirmation of the diagnosis should be made only after at least three months of anticoagulation so that any reversible vascular effect produced by anticoagulation will have occurred (i.e., so that any possible acute residual component will have been neutralized). Anticoagulation should be continued also in the postoperative period if the patient undergoes PTEA, regardless of surgical success, and during clinical treatment of non-operated patients. The choice of an optimal anticoagulant for the treatment of CTEPH is still a subject of controversy in the literature. Vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs) can be used. Traditionally, as well as in the major articles in the literature, VKAs are the most widely used, with a therapeutic target international normalized ratio between 2.0 and 3.0.

Despite the lack of specific studies about CTEPH, DOACs have been rapidly incorporated into the treatment of CTEPH worldwide because of their convenient dosing schedules, stable pharmacokinetic properties, safety profile in terms of major bleeding, and good results, as well as their good acceptance in the context of acute PTE. In 2016 in Germany, 51.0% and 46.2% of 392 patients diagnosed with CTEPH received anticoagulation with DOACs and VKAs, respectively. In Brazil, a case series of patients with CTEPH showed that the use of DOACs in this situation was safe and efficient, regardless of the surgical status of the patients. However, a study conducted in the UK suggests caution in the use of DOACs in CTEPH. In that multicenter, retrospective study, 794 and 206 patients were treated with VKAs and DOACs, respectively, after PTEA. There were no differences in improvement in hemodynamics or functional status after surgery between the two groups, nor were there differences in major bleeding over a follow-up of 612 ± 702 days (0.7% per person/year). However, venous thromboembolism recurrence was higher in those treated with DOACs than in those treated with VKAs (4.62% vs. 0.76% per person/year; p = 0.008), with no differences in survival. Definitive conclusions about the role of DOACs in CTEPH still require further evidence from prospective studies or data from large registries. Therefore, the use of DOACs as the drugs of choice for patients with CTEPH still cannot be recommended. In addition, it is worthy of note that the use of DOACs in patients with antiphospholipid syndrome is not recommended to date because some studies have reported an increased rate of thromboembolic events in the group treated with DOACs when compared with the group treated with VKAs.

**Surgical treatment: PTEA**

The presence of fibrous material obstructing the vascular lumen (Figure 6) shows why PTEA is the treatment of choice for patients with CTEPH. The surgical results are excellent, depending on the level of experience of the referral center, as well as on appropriate patient selection. Patients with CTEPH who undergo PTEA have a better prognosis than do non-operated patients, even when we consider that up to half of the operated patients may still have some degree of PH after the surgical procedure. It is important not to confuse PTEA with embolectomy, which consists in removing only acute (nonendothelialized) thrombi and is used as reperfusion therapy in acute PTE.

**Referral centers**

Facilities that have adequate infrastructure to perform PTEA and BPA and have a multidisciplinary team with clinicians, surgeons, radiologists, and intensivists, are considered referral centers for CTEPH. The team should be experienced in the management of this condition, should be prepared for the perioperative management of patients with CTEPH, and should perform at least 10 PTEAs per year. Less-experienced centers, which perform fewer than 10 PTEAs per year, reported higher mortality rates than did centers that perform more than 50 PTEAs per year (8.8% and 3.4%, respectively). Ideally, referral centers for CTEPH should strive for excellence, performing more than 20 PTEAs per year, with mortality rates < 10%.

**Patient selection**

Patient selection considers the amount of surgically accessible thromboembolic material, as well as its effects on pulmonary vascular resistance (PVR), in order to determine the potential hemodynamic improvement that may result from the surgical intervention. The concept of proportionality between the extent of obstruction and the hemodynamic presentation is somewhat subjective and is related to the level of experience of the center. In certain situations, getting a second opinion from experienced centers regarding operability might be useful for novice centers. In a study that evaluated pharmacological interventions in patients with CTEPH, in which assessment of operability was confirmed or not by centers with wide experience in the surgical management of CTEPH, 69 (22%) of 312 patients who were initially regarded as technically inoperable were reclassified as viable candidates for PTEA, clearly demonstrating the role that the learning curve plays in the decision making of whether or not to recommend the surgical intervention and justifying the requirement that, in
order for a center to be classified as a referral center, it should perform a minimum number of PTEAs. In the decision making of whether or not to recommend PTEA, factors associated with favorable surgical results should be considered, such as a history of deep vein thrombosis/PTE, absence of comorbidities, absence of signs of right heart failure, functional class II or III status, clear proportionality between the imaging abnormalities and the hemodynamic data, bilateral lower lobe disease, PVR less than 1,000 dyn · s · cm⁻⁵, and high pulse pressure. The absence of these characteristics does not contraindicate PTEA, but indicates higher surgical risk, and should therefore be weighed against the level of experience of the center in performing the surgical procedure.

A specific population to be considered to be selected for PTEA is that of patients with unilateral occlusion of one of the main branches of the pulmonary artery, also known as complete pulmonary vascular exclusion (see Figure 4, left lung). In such cases, although the patients are usually younger and have lower pulmonary artery pressure and lower PVR, local factors can make it difficult to perform PTEA and can compromise the surgical result. It is not uncommon, in cases of complete unilateral pulmonary vascular exclusion, that the arterial bed distal to the obstruction shows severe postobstructive arteriopathy or remains hypoplastic, causing inadequate reperfusion despite PTEA. Therefore, cases of unilateral pulmonary artery occlusion should be considered a priority for PTEA, which should be performed before the development of a postobstructive arteriopathy.

Given the low rates of venous thromboembolism in the postoperative period after PTEA, most centers of excellence have abandoned the practice of inserting an inferior vena cava filter prior to surgery. The recommendation is to restart anticoagulation as early as possible, taking into account perioperative bleeding status and the presence of a coagulopathy, as well as the presence of other comorbidities.

**Surgical procedure**

PTEA is performed through a longitudinal median sternotomy using cardiopulmonary bypass (CPB), with the patient being cooled to 18-20°C. This is followed by a period of total circulatory arrest (TCA) of up to 20 min, during which either the right or the left pulmonary artery is approached (Figure 7) and the obstructive fibrous material is removed. Next, CPB is resumed, and blood is recirculated for 10 min, after which there is one more cycle of TCA for the contralateral approach. In most cases, two periods of TCA are sufficient, one for each side approached, but, if necessary, more periods of TCA can be performed until the pulmonary arteries are completely unblocked. After the last period of TCA, CPB is resumed and the patient is slowly rewarmed, at which point other interventions can be made, such as coronary artery revascularization or correction of congenital malformations. Given the need for long CPB time with periods of TCA, measures such as protection...
of the brain by local cooling and assessment of brain activity should be implemented to minimize adverse effects. In addition, anesthetic care, perioperative mechanical ventilation strategies, anticoagulation management, and adequate hemodynamic monitoring are of vital importance, as are anesthesiologists and intensivists trained in performing this type of surgery and in providing extracorporeal membrane oxygenation (ECMO), if necessary. Despite the extent of the surgical procedure, the European registry shows that operated patients have significantly greater survival than non-operated patients, underscoring the role of PTEA as the first-line treatment for eligible patients. On the basis of intraoperative findings, patients are classified into resection categories, which are associated with surgical benefit and long-term prognosis (Chart 4).

The major complications of PTEA are hemodynamic and respiratory. Right ventricular dysfunction in the immediate postoperative period can make it difficult to discontinue CPB. Venoarterial ECMO, although rarely necessary, can provide a bridge to right ventricular recovery. Another complication is residual PH, which occurs in up to 50% of the patients, although a recent meta-analysis involving 4,868 patients reported its presence in approximately 25% of the operated patients. Pulmonary reperfusion injury is a severe respiratory complication that occurs most frequently in the first 48 h after surgery and can cause inflammatory pulmonary edema and severe hypoxemia. In some cases, venovenous ECMO may be necessary for ventilatory support.

The impact of PTEA on the right ventricle suggests the presence of reverse remodeling with a reduction in ventricular volumes and mass, as well as an improvement in ventricular ejection fraction. Moderate to severe tricuspid insufficiency is common in patients with CTEPH but in general does not need to be corrected during PTEA, given the reduction in right ventricular dimensions after the reduction in PVR. Bilateral lung transplantation (exceptionally heart-lung transplantation) is the surgical treatment for patients with PH refractory to other therapies who have no contraindications to this procedure. Patients with CTEPH rarely undergo lung transplantation, since they respond significantly to other therapies.

**BPA**

For patients with CTEPH who have residual PH (after surgery) or for whom surgery is not feasible

---

**Figure 7.** Image of the surgical field of a patient undergoing pulmonary thromboendarterectomy. The pulmonary artery is sectioned longitudinally (arrowhead); an organized white thrombus can be seen within the pulmonary artery, adjacent to the dissecting clamps. There is no blood flow through the pulmonary artery, given that the patient is on cardiopulmonary bypass during a period of total circulatory arrest (cannulas on the left).
(for technical reasons or because of thrombus inaccessibility), treatment options used to be limited to clinical treatment or pulmonary transplantation. However, since the late 1990s, reports of pulmonary artery catheterization procedures for dilation of chronically obstructed branches have been published. BPA, or simply pulmonary angioplasty, is currently an important resource for the treatment of patients with CTEPH.

BPA consists in the insertion a balloon-tipped catheter that can be used to dilate systemic arteries (e.g., femoral, renal, or even coronary arteries) and the subsequent inflation of the balloon within the chosen vessel, without the need for prostheses, such as stents (Figure 8), or the use of thrombolitics or thrombus fragmentation techniques, as can occur in acute PTE. The balloon is inflated to generate enough pressure to disrupt the fibrin network or displace it radially, producing an improvement in local blood flow and an increase in the diameter of the treated vessel, thus leading to a reduction in PVR.

Because the disease is rarely limited to a single area, this treatment is repeated approximately 6-8 times (sessions) for each patient, since approaching more than 4 segments in the same session increases the risk of complications, such as reperfusion edema or rupture of vessels (causing alveolar hemorrhage). From the first reports to more consistent studies, BPA has gradually been incorporated into the treatment algorithm for CTEPH, because the results of this intervention have shown that it can improve hemodynamics, improve symptoms, and increase exercise capacity and right ventricular function, with significantly reduced rates of complications. Retrospective studies have shown that the benefits of BPA also persist in the medium term, and study groups outside Japan were able to reproduce encouraging results. A meta-analysis of 12 observational studies (a total of 493 patients) reported a 2-year mortality rate of 1.3% in patients who underwent BPA, a rate that is significantly lower than that associated with the pharmacological treatment alone. The role of BPA in patients with surgically resectable lesions but for whom surgery is contraindicated because of comorbidities or who refuse surgery has yet to be established.

BPA, as well as PTEA, should be performed at referral centers by professionals trained in the procedure.

**Pharmacological treatment**

**Technically inoperable CTEPH**

All patients with CTEPH should be assessed for eligibility for PTEA at a referral center, as defined previously, because PTEA is potentially curative. However, given that not all patients are eligible for PTEA, either because of the presence of inaccessible thrombi or because PVR is disproportionately high for the degree of vascular obstruction seen on imaging studies, pharmacological treatment, such as BPA, is an alternative.

Three randomized, placebo-controlled clinical trials (Table 2) reported the benefits of using PAH-specific medications in patients with CTEPH who are inoperable (functional class II-IV). The medications evaluated...
were bosentan, (75) riociguat, (76) and macitentan. (77) Those trials showed different clinical endpoints. In the trial regarding bosentan, (75) the primary endpoint was a composite of an increase in six-minute walk distance (6MWD) and a reduction in PVR, whereas in the trial regarding riociguat, (76) it was an increase in mPAP. In the trial regarding macitentan, (77) the primary endpoint was a reduction in PVR. In addition, two of the trials were phase III trials, (75,76) whereas one was a phase II trial. (77) The trials regarding riociguat and macitentan (76,77) showed positive outcomes, whereas that regarding bosentan, (75) which had a composite primary endpoint, the results cannot be considered positive because it showed an effect only in reducing PVR.

A meta-analysis involving 6 studies and 565 patients with CTEPH showed that the use of PAH-targeted drugs in this population led to a significant hemodynamic improvement, as well as to an improvement in symptoms, functional class, and exercise capacity. No differences were found in mortality or in the incidence of severe adverse events. (78)

**Residual PH**

Although PTEA can be curative, recent data suggest that approximately 25% of the operated patients have some degree of residual PH. (80) Some doubt exists regarding cutoff values for defining residual PH after PTEA. Whereas prospective studies have used the traditional cutoff value of 25 mmHg for defining it, (76) a cohort study of 880 patients who had been operated on at one of eight centers in the United Kingdom reported that a postoperative mPAP of 38 mmHg and postoperative PVR > 425 dyn · s · cm⁻⁵ correlated with a worse prognosis. (12) Currently, it is recommended that an mPAP value of 30 mmHg, invasively determined 3-6 months after PTEA, (79) be used to define the presence of significant residual PH. This value comes from the data analysis carried out in that cohort study, (12) which showed that an mPAP > 30 mmHg in the postoperative period after PTEA was associated with higher long-term mortality. The aforementioned trials (75,76) included patients with residual PH, defined as an mPAP ≥ 25 mmHg and PVR ≥ 300 dyn · s · cm⁻⁵, more than six months after PTEA. In the trial regarding bosentan, (75) a reduction in PVR was observed also in the patients with residual PH, but there was no improvement in exercise capacity. In that regarding riociguat, (77) there was an improvement in 6MWD and a reduction in PVR also in the subgroup of patients who had previously been operated on. Macitentan was not evaluated in patients with residual PH. (77) Currently, riociguat is the only medication that has been approved by the American, European, and Brazilian regulatory agencies for the treatment of technically inoperable CTEPH or residual PH.

**Combined pharmacological treatment**

Regarding the macitentan trial, (77) 61% of the patients had already been treated with a phosphodiesterase-5 inhibitor and/or an oral or inhaled prostacyclin when they were started on either macitentan or placebo. The efficacy of macitentan was similar between those who had previously been treated and those who had not. (77) Other combinations of PH-targeted drugs have not been prospectively studied in CTEPH. The combination of riociguat and a phosphodiesterase-5 inhibitor is contraindicated; a study of one such combination reported a lack of benefit and a high rate of discontinuation due to systemic arterial hypotension in patients with PAH. (80)

| Study       | Jaïs et al.  | Ghofrani et al. a | Ghofrani et al. b |
|-------------|--------------|-------------------|-------------------|
| Drug        | Bosentan     | Riociguat         | Macitentan        |
| Dosing schedule | 125 mg p.o., bid | 0.5-2.5 mg p.o., tid | 10 mg/day p.o., qd |
| Number of patients | 157           | 261               | 80               |
| Duration, weeks | 16           | 16                | 16 and 24        |
| Residual or recurrent PH | 41 (29.9%) | 72 (27.6%) | - |
| Previous use of PH-specific medication | - | - | 49 (61.3%) |
| Baseline 6MWD, m | 342 ± 84   | 347 ± 80          | 352 ± 81         |
| Effect on 6MWD, m | +2           | +46               | +34              |
| Baseline PVR, dyn · s · cm⁻⁵ | 783 (95% CI: 703-861) | 787 ± 422 | 957 ± 435 |
| Effect on PVR, % | -24          | -31               | -16              |
| Major adverse effects | Peripheral edema | Headache | Peripheral edema |
|                    | (13% vs. 7.5%) | (25% vs. 14%) | (23% vs. 10%) |
|                    | Hepatotoxicity | Hypertension | ↓ hemoglobin |
|                    | (7.8% vs. 1.3%) | (9% vs. 3%) | (15% vs. 0) |

* Values expressed as n or as mean ± SD. aWe also included patients with residual PH after pulmonary thromboendarterectomy. bPVR at week 16 and 6MWD at week 24. cDrug versus placebo.
**PH medications as “bridging to surgery”**

The evidence supporting pharmacological treatment as bridging to surgery is scarce. International registry data have shown delayed referral to surgery and worse outcomes in those patients treated prior to referral.\(^{(50,83)}\) Recently, a case series has demonstrated some benefit of using pharmacological therapy as bridging to surgery in a population with more severe hemodynamic impairment.\(^{(82)}\) Nevertheless, clinical treatment for improving the hemodynamic status of patients prior to the surgical procedure is not recommended as part of the routine treatment of CTEPH. Clinical treatment can be considered in selected cases only at referral centers with wide experience in the surgical treatment of patients with CTEPH, so that it will not lead to a delay in accessing the treatment of choice.

**Patients either not eligible for surgery because of comorbidities or who refuse surgery**

Patients with accessible thrombi but who were either not eligible for surgery because of comorbidities or refused to undergo surgery were not included in the studies presented above; such patients require an individualized approach.

**Pharmacological treatment or angioplasty**

One study included 105 patients with CTEPH not undergoing PTEA who were randomized either to receive riociguat or to undergo BPA in one of 14 centers in France.\(^{(83)}\) In that study, the efficacy of BPA was greater, given that it reduced PVR by 60%, compared with 32% for riociguat (p < 0.0001). In addition, the proportion of patients who improved at least one functional class was higher among those undergoing BPA than among those treated with riociguat (88% vs. 49%; p < 0.0001). The reduction in brain natriuretic peptide levels was also 67% higher in the BPA group than in the riociguate group (p < 0.0001). There was no difference in 6MWD between the groups. The benefits of BPA came at a price. The proportion of patients with at least one adverse event was higher among those undergoing BPA than among those treated with riociguat (50% vs. 26%), as was the proportion of patients with at least one severe adverse event directly related to treatment (14% vs. 9%). None of the patients discontinued treatment because of adverse events, and there were no deaths during the 26 weeks of the study. These data suggest that BPA should be tried before pharmacological treatment with riociguat in patients with CTEPH who are not eligible for surgery. If BPA is not completely successful in normalizing the patient’s pressure, pharmacological treatment with riociguat would then be indicated.\(^{(1)}\) It should be emphasized, however, that that study\(^{(83)}\) was the first to propose such an approach and that the long-term results of BPA as an initial treatment option if PTEA is not possible—results that would define the role of BPA in this setting—remain unknown. Nevertheless, this treatment option can be accepted as a possibility for patients who are not candidates for surgery. If BPA is not readily available, it is advisable to start pharmacological therapy so that there is no delay in initiating treatment.

**Multimodal treatment**

The combination of different therapeutic modalities is already a reality in CTEPH. There are reports and case series on different combinations of therapeutic strategies, such as PTEA plus pre- and/or post-operative drugs, BPA plus drugs, and, more recently, the combination of PTEA, BPA, and drugs. This last combination is still an individualized approach and depends on the location of the obstruction, the severity of hemodynamic impairment, and the expertise of the team.\(^{(84)}\) Ongoing long-term prospective studies may clarify the role of combined methods in the treatment of CTEPH, as well as the indications and the appropriate timing for each intervention.

The algorithm proposed for the therapeutic approach to CTEPH is described in Figure 9.

**Follow-up**

Patients with CTEPH, whether they undergo PTEA or not, should be evaluated at least every 3-6 months. The factors assessed include clinical variables (functional class, symptom progression, signs of right heart failure); biochemical markers (natriuretic peptides); echocardiography and/or cardiac MRI (right ventricular function by tricuspid annular plane systolic excursion [TAPSE] or ejection fraction, atrial dilatation, presence of pericardial effusion); exercise testing (either 6MWD or oxygen consumption and ventilatory equivalent during CPET); and hemodynamic variables (right atrial pressure, cardiac index, and mixed venous oxygen saturation). At each visit, patient risk should be stratified on the basis of these variables.\(^{(85)}\) There are some risk stratification models that were initially used in PAH and have currently been validated in CTEPH,\(^{(96,87)}\) and the therapeutic target is to maintain patients in the low-risk category all the time (Table 3), with an increase in quality of life.\(^{(86)}\) CPET can also be used in the assessment of the severity of CTEPH and in the follow-up of patients with CTEPH, but therapeutic target thresholds have yet to be defined for this population.

**Screening for CTEPH after acute PTE**

All patients who have acute PTE should be clinically evaluated at 3-6 months of follow-up. At follow-up visits, in addition to the assessment of symptoms, attention should be paid to risk factors that are present and are predictors of an increased risk of CTEPH, such as recurrent venous thromboembolism, young age, unprovoked venous thromboembolism, extensive filling defects, signs of right ventricular dysfunction (e.g., pulmonary artery systolic pressure > 60 mmHg and/or right ventricular hypertrophy), and previous
There is no recommendation that all survivors of acute PTE should be actively investigated. However, patients with persistent or recurrent dyspnea or with limited exercise capacity three months after treatment of the acute event should be assessed for CTEPH. The initial test is echocardiography. If
there are findings indicating intermediate or high likelihood of PH, ventilation/perfusion lung scintigraphy should be performed. In cases with a low likelihood of PH, additional factors should be observed, such as natriuretic peptide levels, risk factors for CTEPH both during the acute event and within the context of the patient, and, eventually, CPET results. CPET is a maximal exercise test, the results of which may be suggestive of CTEPH, which would then indicate the need for further investigation with echocardiography and, subsequently, RHC. In addition, CPET allows the identification of other mechanisms that cause dyspnea in this population of patients who do not have CTEPH.

There is as yet no defined approach to patients with pulmonary thromboembolic disease, that is, those with residual thrombi and no PH at rest. It is suggested that such patients also be referred to referral centers for an individualized approach.

**FINAL CONSIDERATIONS**

Chart 5 summarizes the recommendations for the management of CTEPH.
Risk factors for chronic thromboembolic pulmonary hypertension [Article in Spanish]. Arch Bronconeumol. 2010;46(12):628-633. https://doi.org/10.1161/JAHA.107.156000

References

11. Dorfmüller P, Günther S, Ghigna MR, Thomas de Montpréville V, Boulette D, Paul JF, et al. Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature. Eur Respir J. 2014;44(4):1275-1288. https://doi.org/10.1183/09031936.00169113

12. Cannon JE, Su L, Kielty DG, Page K, Toshner M, Swietek E, et al. Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy: Results From The United Kingdom National Cohort. Circulation. 2016;133(18):1761-1771. https://doi.org/10.1161/CIRCULATIONAHA.115.019470

13. Cozquer N, Weilenmann D, Stolz D, Popov V, Azzola A, Fellraith JM, et al. A Multicentre observational survey for the detection of CTEPH following pulmonary embolism. Eur Respir J. 2018;51(4):170259. https://doi.org/10.1183/13993003.02505-2017

14. Pengo V, Lensing AW, Prins MH, Arrowood M, Davidson BL, Tiozzo F, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004;350(22):2257-2264. https://doi.org/10.1056/NEJMoa0402724

15. Martí D, Gómez V, Escobar C, Wagner C, Zamarro C, Sánchez D, et al. Incidence of symptomatic and asymptomatic chronic thromboembolic pulmonary hypertension [Article in Spanish]. Arch Bronconeumol. 2010;46(12):628-633. https://doi.org/10.1161/JAHA.107.156000

16. Endé-Verhaar YM, Cannegieter SC, Vonk Noordegraaf A, Delcroix M, Prutszky P, Maruihu AT, et al. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. Eur Respir J. 2017;49(2):160792. https://doi.org/10.1183/13993003.01792-2016

17. Pepeke-Zaia J, Janss P, Kim NH, Naeije R, Simonneau G. Chronic thromboembolic pulmonary hypertension: role of medical therapy. Eur Respir J. 2013;41(4):856-990. https://doi.org/10.1183/09031936.0021612

18. Pepeke-Zaia J, Delcroix M, Lang I, Mayer E, Janss P, Ambroz D, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation. 2011;124(18):1973-1981. https://doi.org/10.1161/CIRCULATIONAHA.110.015008

19. Hoepf MM, Mayer E, Simonneau G, Rubin LJ. Chronic thromboembolic pulmonary hypertension. Circulation. 2006;113(18):2012-2020. https://doi.org/10.1161/CIRCULATIONAHA.106.602565

20. Fernandes CJ, Morinaga LTK, Alves JL Jr, Castro MA, Calderaro D, Jardim CV, et al. Cancer-associated thrombosis: the when, how and why. Eur Respir Rev. 2019;28(151):180119. https://doi.org/10.1183/16000617.01119-2018

21. Lang IM, Pavesanto R, Bonderman D, Yuan JX. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J. 2013;41(2):462-468. https://doi.org/10.1183/09031936.0043912

22. Morris TA, Marsh JJ, Chiles PG, Auger WR, Fedullo PF, Woods VL Jr. Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis. Am J Respir Crit Care Med. 1999;160(1):1270-1275. https://doi.org/10.1164/rccm.199906-6160C

23. Dodson MW, Allen-Brady K, Brown LM, Elliott CG, Cannon-Deer CM, et al. Role for staphylococci in misguided thrombus resolution of chronic thromboembolic pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2008;28(4):678-684. https://doi.org/10.1161/ATVBAHA.107.156000

24. Krieg VJ, Hobbhahn L, Liebetan C, Guth S, Kömeli S, Troidl C, et al. Risk factors for chronic thromboembolic pulmonary hypertension - Importance of thyroid disease and function. Thromb Res. 2020;185:20-26. https://doi.org/10.1016/j.thromres.2019.10.025

25. Lang IM, Simonneau G, Pepeke-Zaia JW, Mayer E, Ambroz D, Blanco I, et al. Factors associated with diagnosis and operability of chronic thromboembolic pulmonary hypertension. A case-control study. Thorax. 2013;110(1):S3-91. https://doi.org/10.1136/thoraxjnl-2012-202997

26. Herdy AH, Ritt LE, Stein R, Arajoo CG, Milanesi M, Meneghelo RS, et al. Cardiopulmonary Exercise Test: Background, Applicability and Interpretation. Arq Bras Cardiol. 2016;107(6):467-481. https://doi.org/10.5935/abc.20160171

27. Bonderman D, Jakowitsch J, Kleinwort W, et al. Pulmonary vascular reactivity and prognosis in patients with chronic thromboembolic pulmonary hypertension: a pilot study. Circulation. 2009;119(2):298-305. https://doi.org/10.1161/CIRCULATIONAHA.108.794610

28. Fernandes CJ, Alves-Junior JL, Gavilanes P, Prada LF, Morinaga LK, Souza R. New antioxidants for the treatment of venous thromboembolism. J Bras Pneumol. 2016;42(2):146-154. https://doi.org/10.1590/0034-6641-2015-2009.
61. Yusen RD, Wilkins H, Fuge J, Schäfers HJ, Guth S, Wiedenroth CB, et al. Incidence and characteristics of chronic thromboembolic pulmonary hypertension in Germany. Clin Res Cardiol. 2018;107(1):548-553. https://doi.org/10.1007/s00392-018-1215-5

62. Delcroix M, Lang I, Pepke-Zaba J, Jansa P, D’Armini AM, Fadel E, et al. Long-term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry. Circulation. 2016;133(9):859-871. https://doi.org/10.1161/CIRCULATIONAHA.115.016522

63. Jenkins DP, Biederman A, D’Armini AM, Dartevelle PG, Gan HL, et al. Management of antiphospholipid syndrome. Ann Rheum Dis. 2019;78(2):155-161. https://doi.org/10.1136/annrheumdis-2018-213846

64. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2019;40(36):3053-3102. https://doi.org/10.1093/eurheartj/ehz328

65. Jenkins DP, Biederman A, D’Armini AM, Fadel E, D’Armini AM, Mayer E, et al. Pulmonary endarterectomy in the management of chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2017;26(143):160111. https://doi.org/10.1183/16000617.1111-2016

66. Sugiyama K, Suzuki S, Fujiyoshi T, Koizumi N, Sato M, Ogino H. Extracorporeal membrane oxygenation after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. J Card Surg. 2019;34(8):1326-1331. https://doi.org/10.1111/jocs.14052

67. Hsieh WC, Jansa P, Huang WC, Nishizaki M, Mora M, Lindner J. Residual pulmonary hypertension after pulmonary endarterectomy: A meta-analysis. J Thorac Cardiovasc Surg. 2018;156(3):1275-1287. https://doi.org/10.1016/j.jtcvs.2018.04.110

68. D’Armini AM, Zanotti G, Ghio S, Magrini G, Pozzi M, Scelsi L, et al. Reverse right ventricular remodeling after pulmonary endarterectomy. J Thorac Cardiovasc Surg. 2007;133(1):162-168. https://doi.org/10.1016/j.jtcvs.2006.08.059

69. Yosen RD, Edwards LB, Dipchand AI, Goldfarb SB, Kucheryavaya AV, Leevey BJ, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Lung and Heart-Lung Transplant Report-2016. Focus Theme: Primary Diagnostics Indications for Transplant. J Heart Lung Transplant. 2016;35(10):1170-1184. https://doi.org/10.1016/j.healun.2016.09.001

60. Feinstein JA, Goldhaber SZ, Lock JE, Fernandes SM, Landzberg MJ. Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension. Circulation. 2001;103(1):10-13. https://doi.org/10.1161/01.CIR.103.1.10

61. Ogo T. Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension. Curr Opin Pulm Med. 2015;21(5):425-431. https://doi.org/10.1097/MCP.0000000000000188

62. Olsson KM, Wiedenroth CB, Kamp JC, Breithaecker A, Fuge J, Krombach GA, et al. Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience. Eur Respir J. 2017;49(6):160249. https://doi.org/10.1183/13993003.02409-2016

63. Ogawa A, Satoh T, Fukuda T, Sugimura K, Fukumoto Y, Emoto N, et al. Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: Results of a Multicenter Registry. Circ Cardiovasc Qual Outcomes. 2017;10(11):e004029. https://doi.org/10.1161/CIRCOUTCOMES.117.004029

64. Kawakami T, Ogawa A, Miyaj K, Mizoguchi H, Shimokawahara H, Naito T, et al. Novel Angiographic Classification of Each Vascular Lesion in Chronic Thromboembolic Pulmonary Hypertension Based on Selective Angiogram and Results of Balloon Pulmonary Angioplasty. Circ Cardiovasc Interv. 2016;9(10):e003318. https://doi.org/10.1161/CIRCINTERVENTIONS.115.003318

65. Mizoguchi H, Ogawa A, Munemasa M, Mikouchi H, Ito H, Matsubara S. Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv. 2012;5(6):748-755. https://doi.org/10.1161/CIRCINTERVENTIONS.112.971077

66. Kataoka M, Inami T, Hayashida K, Shimura N, Ishiguro H, Abe T, et al. Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv. 2012;5(6):756-762. https://doi.org/10.1161/CIRCINTERVENTIONS.112.971390

67. Fukui S, Ogo T, Goto Y, Ueda J, TsujI A, Sanda Y, et al. Exercise intolerance and ventilatory inefficiency improved, early after balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. Int J Cardiol. 2015;180:66-68. https://doi.org/10.1016/j.ijcard.2014.11.187

68. Fukui S, Ogo T, Morita Y, TsujI A, Tatsushi E, Ozaki K, et al. Right ventricular reverse remodeling after balloon pulmonary angioplasty. Eur Respir J. 2014;43(8):1394-1402. https://doi.org/10.1183/09031936.0012914

69. Sugimura K, Fukushima Y, Satoh K, Nochioka K, Miura Y, Akiz T, et al. Percutaneous trans-luminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension. Circ J. 2012;76(2):485-488. https://doi.org/10.1253/circj.CJ-11-1217

70. Inami T, Kataoka M, Yanagisawa R, Ishiguro H, Shimura N, Fukuda M, et al. Long-Term Outcomes After Percutaneous Transluminal Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension. Circulation. 2016;134(24):2030-2032. https://doi.org/10.1161/CIRCULATIONAHA.116.024021

71. Brenot P, Jais X, Taniguchi Y, Garcia Alonso C, Gerardin B, Masrot S, et al. French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019;53(S1):1802095. https://doi.org/10.1183/13993003.02095-2018

72. Tanabe N, Kawakami T, Satoh T, Matsubara H, Nakashini N, Gogo H, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: A systematic review. Respir Res. 2018;19(6):343-344. https://doi.org/10.1186/s12931-018-0833-8

73. Jais X, D’Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFIT (Bosentan Effect in InopErable Forms of chronic Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol. 2008;52(21):2127-2134. https://doi.org/10.1016/j.jacc.2008.08.059

74. Ghofrani HA, D’Armini AM, Griminger F, Hoepf MM, Jansa P, Kim NH, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319-329. https://doi.org/10.1056/NEJMoa1209657

75. J Bras Pneumol. 2020;46(4):e20200204
78. Zhang J, Li JM, Huang ZS, Xu JC, Fan Y. A meta-analysis of randomized controlled trials in targeted treatments of chronic thromboembolic pulmonary hypertension. Clin Respir J. 2019;13(7):467-479. https://doi.org/10.1111/crj.13034

79. Hooper MM. Residual Pulmonary Hypertension After Pulmonary Endarterectomy: The Fog Is Clearing. Circulation. 2016;133(18):1731-1733. https://doi.org/10.1161/CIRCULATIONAHA.116.022596

80. Galié N, Müller K, Sculise AV, Grün E. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Eur Respir J. 2015;45(5):1314-1322. https://doi.org/10.1183/09031936.00105914

81. Jensen KW, Kerr KM, Fedullo PF, Kim NH, Test VJ, Ben-Yehuda O, et al. Pulmonary hypertensive medical therapy in chronic thromboembolic pulmonary hypertension before pulmonary thromboendarterectomy. Circulation. 2009;120(13):1248-1254. https://doi.org/10.1161/CIRCULATIONAHA.109.865881

82. Castro MA, Piloto B, Dos Santos Fernandes CJC, Jardim C, Filho WS, Oleas FG, et al. Use of medical therapies before pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension patients with severe hemodynamic impairment. PLoS One. 2020;15(5):e0233063. https://doi.org/10.1371/journal.pone.0233063

83. Jais X, Brenot P, Bouvaist H, Canuet M, Chabanne C, Chaouat A, et al. Late Breaking Abstract - Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: results from the randomised controlled RACE study. Eur Respir J. 2019;54(Suppl 63):RCT1885. https://doi.org/10.1183/13993003.congress-2019.RCT1885

84. Madani M, Ogo T, Simonneau G. The changing landscape of chronic thromboembolic pulmonary hypertension management. Eur Respir Rev. 2017;26(148):170105. https://doi.org/10.1183/16000617.0105-2017

85. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67-119. https://doi.org/10.1093/eurheartj/ehv317

86. Delcroix M, Staehler G, Gall H, Grün E, Held M, Halank M, et al. Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients. Eur Respir J. 2018;52(6):1800248. https://doi.org/10.1183/13993003.0248-2018

87. Humbert M, Farber HW, Ghofrani HA, Benza RL, Busse D, Meier C, et al. Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019;53(6):182004. https://doi.org/10.1183/13993003.02004-2018

88. Fernandes CJ, Martins BC, Jardim CV, Ciconelli RM, Morinaga LK, Breda AP, et al. Quality of life as a prognostic marker in pulmonary arterial hypertension. Health Qual Life Outcomes. 2014;12:130. https://doi.org/10.1186/s12955-014-0130-3

89. Wilkens H, Konstantinides S, Lang IM, Bunck AC, Gerges M, Gerhardt F, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018;272:69 - 78. https://doi.org/10.1016/j.ijcard.2018.08.079

90. Held M, Grün M, Hol R, Hüblner G, Kaiser R, Karl S, et al. Cardiopulmonary exercise testing to detect chronic thromboembolic pulmonary hypertension in patients with normal echocardiography. Respiration. 2014;87(5):379-387. https://doi.org/10.1159/000358565